SNWV - Earnings announcements

Q4 2025 revenues were $13.4 million, up 29.7% from Q4 2024. This was an all-time quarterly record for the Company. Full year 2025 revenues were $44.1 million up 35.0% from full year 2024 revenues. This was an all-time annual record for the Company. Q4 2025 gross margin was 74.7%, versus 77.9% in Q4 2024 and 77.6% in Q3 2025. Full year 2025 gross margin was 77.1% versus 75.2% in 2024. GAAP Operating Income was $2.0 million for Q4 2025 and $4.9 million for full year 2025. Company provides guidance for revenues of $9.6-10.3 million (an increase of 3-10%) for Q1 2026 as compared to Q1 2025 and initiates full year 2026 revenue guidance of 16-25% growth vs 2025 ($51.0-55.0 million). EDEN

EDEN PRAIRIE, Minn., March 20, 2026 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave") (NASDAQ:SNWV), a leading provider of next-generation FDA-approved wound care products, will host a live conference call on Friday, March 27, 2026, at 8:30 AM (ET) to present its Q4 and Full Year 2025 financial results. Telephone access to the call will be available by dialing the following numbers: Participant Dial-in Information  Toll Free: 1-800-343-4136 Toll/International: 1-203-518-9843 Conference ID: SANUWAVE OR click the link for instant telephone access to the event:https://viavid.webcasts.com/starthere.jsp?ei=1753775&tp_key=6ca0a4cd2b Materials for the conference call

Q3 2025 revenues were $11.5 million, up 22% from $9.4 million in Q3 2024. This represents the highest quarterly revenues in Company history. Q3 2025 gross margin was 77.9%, versus 75.5% in Q3 2024. GAAP Operating Income was $1.5 million for Q3 2025 versus $2.0 million in Q3 2024. Q3 2025 included stock-based compensation costs of $1.4 million versus $0 in Q3 2024. Company provides guidance for revenues of $13-$14 million for Q4 2025. EDEN PRAIRIE, Minn., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave") (NASDAQ:SNWV), a leading provider of next-generation FDA-approved wound care products, is pleased to provide its financial results for the three mo

EDEN PRAIRIE, Minn., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave") (NASDAQ:SNWV), a leading provider of next-generation FDA-approved wound care products, will host a live conference call on Friday, November 7, 2025, at 8:30 AM (ET) to present its Q3 2025 financial results. Telephone access to the call will be available by dialing the following numbers: Participant Dial-in Information  Toll Free: 1-800-274-8461 Toll/International: 1-203-518-9814 Conference ID: SANUWAVE OR click the link for instant telephone access to the event:https://viavid.webcasts.com/starthere.jsp?ei=1741017&tp_key=73ef3b515aMaterials for the conference call will be include

Sanuwave announces preliminary revenues of $11.4 million to $11.6 million for the third quarter ended September 30, 2025. This represents the highest quarterly revenues in Company history. Q3 2025 revenue increased between 22% and 24% vs Q3 2024 and between 12% and 14% sequentially vs the prior quarter First nine months of 2025 revenue increased 39-40% vs first nine months of 2024. EDEN PRAIRIE, Minn., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave") (NASDAQ:SNWV), a leading provider of next-generation FDA-approved wound care products, today announced that revenues for the third quarter of 2025 are expected to be in the range of $11.4 to $11.6 millio

Q2 2025 revenues were $10.2 million, up 42% from $7.2 million in Q2 2024. This represents the highest Q2 quarterly revenues in Company history. Q2 2025 gross margin was 78.3%, versus 73.2% in Q2 2024. GAAP Operating Income was $1.9 million for Q2 2025 versus $2.0 million in Q2 2024. Q2 2025 included equity compensation costs of $1.1 million versus $0 in Q2 2024. Company provides guidance for revenues of $12-$12.7 million for Q3 2025. EDEN PRAIRIE, Minn., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave") (NASDAQ:SNWV), a leading provider of next-generation FDA-approved wound care products, is pleased to provide its financial results for the three mon

EDEN PRAIRIE, Minn., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave") (NASDAQ:SNWV), a leading provider of next-generation FDA-approved wound care products, will host a live conference call on Friday, August 8, 2025, at 8:30 AM (ET) to present its Q2 2025 financial results. Telephone access to the call will be available by dialing the following numbers: Participant Dial-in Information  Toll Free: 1-800-245-3047 Toll/International: 1-203-518-9765 Conference ID: SANUWAVE OR click the link for instant telephone access to the event: https://viavid.webcasts.com/starthere.jsp?ei=1723341&tp_key=b9f972bf82Materials for the conference call will be included

Q1 2025 revenues were $9.3 million, up 61% from $5.8 million in Q1 2024. This represents the highest Q1 quarterly revenues in Company history. Q1 2025 gross margin was 79.0%, versus 72.6% in Q1 2024. GAAP Operating Income was $1.0 million for Q1 2025, an increase of $2.0 million from Q1 2024. Company provides guidance for revenue growth of 40-50% for Q2 2025 as compared to Q2 2024 EDEN PRAIRIE, Minn., May 09, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave") (NASDAQ:SNWV), a leading provider of next-generation FDA-approved wound care products, is pleased to provide its financial results for the three months ended March 31, 2025. Q1 2025 ended March 31, 202

EDEN PRAIRIE, Minn., May 05, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave") (NASDAQ:SNWV), a leading provider of next-generation FDA-approved wound care products, will host a live conference call on Friday, May 9, 2025, at 8:30 AM (ET) to present its Q1 2025 financial results. Telephone access to the call will be available by dialing the following numbers: Participant Dial-in Information Toll Free: 1-800-245-3047 Toll/International: 1-203-518-9765 Conference ID: SANUWAVE OR click the link for instant telephone access to the event:https://viavid.webcasts.com/starthere.jsp?ei=1714486&tp_key=88406b4795 Materials for the conference call will b